NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina
dc.contributor.authorBugallo Casal, Ana
dc.contributor.authorCastillo Sánchez, José Antonio
dc.contributor.authorCampos, Francisco
dc.date.accessioned2026-04-24T08:52:05Z
dc.date.available2026-04-24T08:52:05Z
dc.date.issued2025-12-01
dc.date.updated2026-03-27T12:29:40Z
dc.description.abstractCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common genetic form of stroke. It is caused by a cysteine-altering variant in one of the 34 epidermal growth factor-like repeat (EGFr) domains of Notch3. NOTCH3 pathogenic variants in EGFr 1–6 are associated with high disease severity, whereas those in EGFr 7–34 are associated with late stroke onset and increased survival. However, whether and how the position of the NOTCH3 variant directly affects the disease severity remains unclear. In this study, we aimed to generate human-induced pluripotent stem cells (hiPSCs) from patients with CADASIL with EGFr 1–6 and 7–34 pathogenic variants to evaluate whether the NOTCH3 position affects the cell phenotype and protein profile of the generated hiPSCs lines. Six hiPSCs lines were generated: two from patients with CADASIL with EGFr 1–6 pathogenic variants, two from patients with EGFr 7–34 variants, and two from controls. Notch3 aggregation and protein profiles were tested in the established six hiPSCs lines. Cell analysis revealed that the NOTCH3 variants did not limit the cell reprogramming efficiency. However, EGFr 1–6 variant position was associated with increased accumulation of Notch3 protein in pluripotent stem cells and proteomic changes related with cytoplasmic reorganization mechanisms. In conclusion, our analysis of hiPSCs derived from patients with CADASIL support the clinical association between the NOTCH3 variant position and severity of CADASIL.en
dc.description.peerreviewedSI
dc.description.sponsorshipThis study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI17/00540, PI20/01014, PI23/000890, RICORS-ICITUS RD21/0006/0003, RD21/0006/0004, RD24/0009/0022, RD24/0009/0017 and AC23-2/00029. AC23-2/00029 (named as CADANHIS) project has been supported by the EJP RD—European Joint Programme on Rare Diseases—Joint Transnational Call 2023 for Rare Diseases Research Project (JTC 2023). The EJP RD initiative has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N°825575. Finally, this work was supported by grants from the Instituto de Salud Carlos III, PReDICT Project (PMPER24/00021) together with Next-Generation EU funds that finance the actions of the Recovery and Resilience Mechanism.
dc.identifier.citationBugallo-Casal, A., Muiño, E., Bravo, S. B., Hervella, P., Arias-Rivas, S., Rodríguez-Yáñez, M., Vara-León, E., Quintas-Rey, R., Pérez-Gayol, L., Maisterra-Santos, O., Pizarro-Gonzálvez, J., Martorell-Riera, M. R., Vives-Bauzá, C., Fernández-Cadenas, I., Castillo, J., & Campos, F. (2025). NOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASIL. NeuroMolecular Medicine, 27(1). https://doi.org/10.1007/S12017-025-08840-6
dc.identifier.doi10.1007/S12017-025-08840-6
dc.identifier.eissn1559-1174
dc.identifier.essn1559-1174
dc.identifier.issn1535-1084
dc.identifier.urihttps://hdl.handle.net/10347/46963
dc.issue.number1
dc.journal.titleNeuroMolecular Medicine
dc.language.isoeng
dc.publisherSpringer
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/RD24/0009/0017/ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F00540/ES/IMPLANTACION DE LA MEDICINA PERSONALIZADA PARA EL ESTUDIO Y TRATAMIENTO DE ENFERMEDADES CEREBROVASCULARES COMO CADASIL.
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F01014/ES/MODELAJE DE PATOLOGIAS VASCULARES EN PACIENTES DE CADASIL CON FENOTIPO LEVE Y SEVERO.
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación para el periodo 2021-2023/PI23%2F00890/ES/Caracterización de las alteraciones hemostáticas en pacientes que reciben terapia con células CAR-T y su relación con el desarrollo de complicaciones trombóticas y hemorrágicas.
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación para el periodo 2021-2023/AC23_2%2F00029/ES/Historia Natural de CADASIL
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/825575
dc.relation.publisherversionhttps://doi.org/10.1007/s12017-025-08840-6
dc.rights© The Author(s) 2025
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceNeuroMolecular Medicine
dc.subjectCADASIL
dc.subjectDisease modeling
dc.subjectHuman iPSCs
dc.subjectNOTCH3 variant position
dc.subjectProteomic analysis
dc.subjectStem cells
dc.titleNOTCH3 Variant Position Affects the Phenotype at the Pluripotent Stem Cell Level in CADASILen
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number27
dspace.entity.typePublication
oaire.awardNumberRD24/0009/0017
oaire.awardNumberPMPER24/00021
oaire.awardNumberJTC 2023
oaire.funderIdentifier10.13039/501100004587
oaire.funderIdentifier10.13039/100010661
oaire.funderNameInstituto de Salud Carlos III
oaire.funderNameHorizon 2020 Framework Programme
oaire.funderNameEJP RD
relation.isAuthorOfPublication7e2808f2-a23b-498c-b742-61b88b44cdc9
relation.isAuthorOfPublication.latestForDiscovery7e2808f2-a23b-498c-b742-61b88b44cdc9

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2025_nmmed_bugallo_notch3.pdf
Size:
5.43 MB
Format:
Adobe Portable Document Format